Epigallocatechin gallate induce cell death and apoptosis in triple negative breast cancer cells Hs578T

References

• Arslan C, Dizdar O, Altundag K. (2009). Pharmacotherapy of triple-negative breast cancer. Expert Opin Pharmacother, 10, 2081–2093.
   PubMed Web of Science ®Google Scholar
• Bergamaschi D, Samuels Y, Jin B, Duraisingham S, Crook T, Lu X. (2004). ASPP1 and ASPP2: common activators of p53 family members. Mol Cell Biol, 24, 1341–1350.
   PubMed Web of Science ®Google Scholar
• Borska S, Gebarowska E, Wysocka T, Drag-Zalesinska M, Zabel M. (2003). Induction of apoptosis by EGCG in selected tumour cell lines in vitro. Folia Histochem Cytobiol, 41, 229–232.
   PubMed Web of Science ®Google Scholar
• Braicu C, Berindan-Neagoe I, Burz C, Balacescu O, Irimie A. (2009). Catechins therapeutic implications in cancer. Biol Ther Cancer Cell, 1(1), 81–84.
   Google Scholar
• Braicu C, Rugina D, Chedea VS, Tudoran O, Balacescu O, Neagoe I, Socaciu C. (2010). Protective action of different natural flavan-3-ols against aflatoxin B1-related cytotoxicity. J Food Biochem, 4(3), 595–610.
   Google Scholar
• Brenton JD, Carey LA, Ahmed AA, Caldas C. (2005). Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol, 23, 7350–7360.
   PubMed Web of Science ®Google Scholar
• Chedea VS, Braicu C, Socaciu C. (2010). Antioxidant/prooxidant activity of a polyphenolic grape seed extract. Food Chem, 121, 132–139.
   Web of Science ®Google Scholar
• Chisholm K, Bray BJ, Rosengren RJ. (2004). Tamoxifen and epigallocatechin gallate are synergistically cytotoxic to MDA-MB-231 human breast cancer cells. Anticancer Drugs, 15, 889–897.
   PubMed Web of Science ®Google Scholar
• Dai Y, Lawrence TS, Xu L. (2009). Overcoming cancer therapy resistance by targeting inhibitors of apoptosis proteins and nuclear factor-κB. Am J Transl Res, 1, 1–15.
   PubMedGoogle Scholar
• Denoeud J, Moser M. (2011). Role of CD27/CD70 pathway of activation in immunity and tolerance. J Leukoc Biol, 89, 195–203.
   PubMed Web of Science ®Google Scholar
• Deveraux QL, Takahashi R, Salvesen GS, Reed JC. (1997). X-linked IAP is a direct inhibitor of cell-death proteases. Nature, 388, 300–304.
   PubMed Web of Science ®Google Scholar
• Dufner A, Pownall S, Mak TW. (2006). Caspase recruitment domain protein 6 is a microtubule-interacting protein that positively modulates NF-κB activation. Proc Natl Acad Sci USA, 103, 988–993.
   PubMed Web of Science ®Google Scholar
• Emery JG, McDonnell P, Burke MB, Deen KC, Lyn S, Silverman C, Dul E, Appelbaum ER, Eichman C, DiPrinzio R, Dodds RA, James IE, Rosenberg M, Lee JC, Young PR. (1998). Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem, 273, 14363–14367.
   PubMed Web of Science ®Google Scholar
• Foulkes WD, Smith IE, Reis-Filho JS. (2010). Triple-negative breast cancer. N Engl J Med, 363, 1938–1948.
   PubMed Web of Science ®Google Scholar
• Guo S, Lu J, Subramanian A, Sonenshein GE. (2006). Microarray-assisted pathway analysis identifies mitogen-activated protein kinase signaling as a mediator of resistance to the green tea polyphenol epigallocatechin 3-gallate in her-2/neu-overexpressing breast cancer cells. Cancer Res, 66, 5322–5329.
   PubMed Web of Science ®Google Scholar
• Guo S, Liu M, Godwin AK. (2012). Transcriptional Regulation of hTREX84 in Human Cancer Cells. PLoS ONE, 7, e43610.
   PubMedGoogle Scholar
• Huang DC, Strasser A. (2000). BH3-Only proteins-essential initiators of apoptotic cell death. Cell, 103, 839–842.
   PubMed Web of Science ®Google Scholar
• Huang J, Kerstann KW, Ahmadzadeh M, Li YF, El-Gamil M, Rosenberg SA, Robbins PF. (2006). Modulation by IL-2 of CD70 and CD27 expression on CD8+ T cells: importance for the therapeutic effectiveness of cell transfer immunotherapy. J Immunol, 176, 7726–7735.
   PubMed Web of Science ®Google Scholar
• Iwahana H, Yakymovych I, Dubrovska A, Hellman U, Souchelnytskyi S. (2006). Glycoproteome profiling of transforming growth factor-β (TGFβ) signaling: nonglycosylated cell death-inducing DFF-like effector A inhibits TGFβ1-dependent apoptosis. Proteomics, 6, 6168–6180.
   PubMed Web of Science ®Google Scholar
• Kang JS, Bae SY, Kim HR, Kim YS, Kim DJ, Cho BJ, Yang HK, Hwang YI, Kim KJ, Park HS, Hwang DH, Cho DJ, Lee WJ. (2009). Interleukin-18 increases metastasis and immune escape of stomach cancer via the downregulation of CD70 and maintenance of CD44. Carcinogenesis, 30, 1987–1996.
   PubMed Web of Science ®Google Scholar
• Kim J, Zhang X, Rieger-Christ KM, Summerhayes IC, Wazer DE, Paulson KE, Yee AS. (2006). Suppression of Wnt signaling by the green tea compound (-)-epigallocatechin 3-gallate (EGCG) in invasive breast cancer cells. Requirement of the transcriptional repressor HBP1. J Biol Chem, 281, 10865–10875.
   PubMed Web of Science ®Google Scholar
• Kim S, Choi MG, Lee HS, Lee SK, Kim SH, Kim WW, Hur SM, Kim JH, Choe JH, Nam SJ, Yang JH, Kim S, Lee JE, Kim JS. (2009). Silibinin suppresses TNF-α-induced MMP-9 expression in gastric cancer cells through inhibition of the MAPK pathway. Molecules, 14, 4300–4311.
   PubMed Web of Science ®Google Scholar
• Koh KK, Bui MN, Mincemoyer R, Cannon RO 3rd. (1997). Effects of hormone therapy on inflammatory cell adhesion molecules in postmenopausal healthy women. Am J Cardiol, 80, 1505–1507.
   PubMed Web of Science ®Google Scholar
• Kutuk O, Letai A. (2008). Alteration of the mitochondrial apoptotic pathway is key to acquired paclitaxel resistance and can be reversed by ABT-737. Cancer Res, 68, 7985–7994.
   PubMed Web of Science ®Google Scholar
• Letai A, Bassik MC, Walensky LD, Sorcinelli MD, Weiler S, Korsmeyer SJ. (2002). Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell, 2, 183–192.
   PubMed Web of Science ®Google Scholar
• Mitchell C, Yacoub A, Hossein H, Martin AP, Bareford MD, Eulitt P, Yang C, Nephew KP, Dent P. (2010). Inhibition of MCL-1 in breast cancer cells promotes cell death in vitro and in vivo. Cancer Biol Ther, 10, 903–917.
   PubMed Web of Science ®Google Scholar
• Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F, Speed T, Spellman PT, DeVries S, Lapuk A, Wang NJ, Kuo WL, Stilwell JL, Pinkel D, Albertson DG, Waldman FM, McCormick F, Dickson RB, Johnson MD, Lippman M, Ethier S, Gazdar A, Gray JW. (2006). A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell, 10, 515–527.
   PubMed Web of Science ®Google Scholar
• Pan MH, Lin CC, Lin JK, Chen WJ. (2007). Tea polyphenol (-)-epigallocatechin 3-gallate suppresses heregulin-β1-induced fatty acid synthase expression in human breast cancer cells by inhibiting phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase cascade signaling. J Agric Food Chem, 55, 5030–5037.
   PubMed Web of Science ®Google Scholar
• Pianetti S, Guo S, Kavanagh KT, Sonenshein GE. (2002). Green tea polyphenol epigallocatechin-3 gallate inhibits Her-2/neu signaling, proliferation, and transformed phenotype of breast cancer cells. Cancer Res, 62, 652–655.
   PubMed Web of Science ®Google Scholar
• Puig T, Vázquez-Martín A, Relat J, Pétriz J, Menéndez JA, Porta R, Casals G, Marrero PF, Haro D, Brunet J, Colomer R. (2008). Fatty acid metabolism in breast cancer cells: differential inhibitory effects of epigallocatechin gallate (EGCG) and C75. Breast Cancer Res Treat, 109, 471–479.
   PubMed Web of Science ®Google Scholar
• Rahman M, Davis SR, Pumphrey JG, Bao J, Nau MM, Meltzer PS, Lipkowitz S. (2009). TRAIL induces apoptosis in triple-negative breast cancer cells with a mesenchymal phenotype. Breast Cancer Res Treat, 113, 217–230.
   PubMed Web of Science ®Google Scholar
• Reis-Filho JS, Tutt AN. (2008). Triple negative tumours: a critical review. Histopathology, 52, 108–118.
   PubMed Web of Science ®Google Scholar
• Rivas MA, Carnevale RP, Proietti CJ, Rosemblit C, Beguelin W, Salatino M, Charreau EH, Frahm I, Sapia S, Brouckaert P, Elizalde PV, Schillaci R. (2008). TNF α acting on TNFR1 promotes breast cancer growth via p42/P44 MAPK, JNK, Akt and NF-κB-dependent pathways. Exp Cell Res, 314, 509–529.
   PubMed Web of Science ®Google Scholar
• Rochester MA, Riedemann J, Hellawell GO, Brewster SF, Macaulay VM. (2005). Silencing of the IGF1R gene enhances sensitivity to DNA-damaging agents in both PTEN wild-type and mutant human prostate cancer. Cancer Gene Ther, 12, 90–100.
   PubMed Web of Science ®Google Scholar
• Roy A, Baliga M, Katiyar S. (2005). Epigallocatechin-3-gallate induces apoptosis in estrogen receptor–negative human breast carcinoma cells via modulation in protein expression of p53 and Bax and caspase-3 activation. Mol Can Therap, 1(4), 1535–7163.
   Google Scholar
• Scandlyn MJ, Stuart EC, Somers-Edgar TJ, Menzies AR, Rosengren RJ. (2008). A new role for tamoxifen in oestrogen receptor-negative breast cancer when it is combined with epigallocatechin gallate. Br J Cancer, 99, 1056–1063.
   PubMed Web of Science ®Google Scholar
• Shankar S, Ganapathy S, Hingorani SR, Srivastava RK. (2008). EGCG inhibits growth, invasion, angiogenesis and metastasis of pancreatic cancer. Front Biosci, 13, 440–452.
   PubMed Web of Science ®Google Scholar
• Singh BN, Shankar S, Srivastava RK. (2011). Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications. Biochem Pharmacol, 82, 1807–1821.
   PubMed Web of Science ®Google Scholar
• Stuart E, Larsen L. (2007). Rosengren R. Potential mechanisms for the synergistic cytotoxicity elicited by 4-hydroxytamoxifen and epigallocatechin gallate in MDAMB-231 cells. Int J Oncol, 6(30), 1019–6439.
   Google Scholar
• Stuart EC, Scandlyn MJ, Rosengren RJ. (2006). Role of epigallocatechin gallate (EGCG) in the treatment of breast and prostate cancer. Life Sci, 79, 2329–2336.
   PubMed Web of Science ®Google Scholar
• Tang SN, Singh C, Nall D, Meeker D, Shankar S, Srivastava RK. (2010). The dietary bioflavonoid quercetin synergizes with epigallocathechin gallate (EGCG) to inhibit prostate cancer stem cell characteristics, invasion, migration and epithelial-mesenchymal transition. J Mol Signal, 5, 14.
   PubMedGoogle Scholar
• Tang Y, Zhao DY, Elliott S, Zhao W, Curiel TJ, Beckman BS, Burow ME. (2007). Epigallocatechin-3 gallate induces growth inhibition and apoptosis in human breast cancer cells through survivin suppression. Int J Oncol, 31, 705–711.
   PubMed Web of Science ®Google Scholar
• Thangapazham RL, Passi N, Maheshwari RK. (2007). Green tea polyphenol and epigallocatechin gallate induce apoptosis and inhibit invasion in human breast cancer cells. Cancer Biol Ther, 6, 1938–1943.
   PubMed Web of Science ®Google Scholar
• Thangapazham RL, Singh AK, Sharma A, Warren J, Gaddipati JP, Maheshwari RK. (2007). Green tea polyphenols and its constituent epigallocatechin gallate inhibits proliferation of human breast cancer cells in vitro and in vivo. Cancer Lett, 245, 232–241.
   PubMed Web of Science ®Google Scholar
• Vosjan MJ, Vercammen J, Kolkman JA, Stigter-van Walsum M, Revets H, van Dongen GA. (2012). Nanobodies targeting the hepatocyte growth factor: potential new drugs for molecular cancer therapy. Mol Cancer Ther, 11, 1017–1025.
   PubMed Web of Science ®Google Scholar
• Walter-Yohrling J, Cao X, Callahan M, Weber W, Morgenbesser S, Madden SL, Wang C, Teicher BA. (2003). Identification of genes expressed in malignant cells that promote invasion. Cancer Res, 63, 8939–8947.
   PubMed Web of Science ®Google Scholar
• Wang Z, Fukushima H, Inuzuka H, Wan L, Liu P, Gao D, Sarkar FH, Wei W. (2012). Skp2 is a promising therapeutic target in breast cancer. Front Oncol, 1, 18702.
   Google Scholar
• Yang CS, Wang H. (2011). Mechanistic issues concerning cancer prevention by tea catechins. Mol Nutr Food Res, 55(6), 819–831.
   PubMed Web of Science ®Google Scholar
• Yang JP, Ono T, Sonta S, Kawabe T, Okamoto T. (1997). Assignment of p53 binding protein (TP53BP2) to human chromosome band 1q42.1 by in situ hybridization. Cytogenet Cell Genet, 78(1), 61–62.
   PubMedGoogle Scholar
• Yonezawa T, Kurata R, Kimura M, Inoko H. (2011). Which CIDE are you on? Apoptosis and energy metabolism. Mol Biosyst, 7(1), 91–100.
   PubMed Web of Science ®Google Scholar
• Zhu H, Liu P, Li J. (2012). BAG3: a new therapeutic target of human cancers? http://www.um.es/hh/Reviews-proofs/Zhu%20et%20al.pdf
   Google Scholar